Government-Owned Inventions; Availability for Licensing, 4274-4275 [E7-1377]
Download as PDF
<![CDATA[
4274
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
Type of respondents
Number of
respondents
Frequency of
response
Average burden
hours per
response
Estimated
total burden
hours requested
Requesters—School Personnel .......................................................
Requestors—Community Leaders ...................................................
200
200
1
1
0.08
0.08
16
16
Total ..........................................................................................
400
............................
............................
32
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(2) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (3) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plans, contact
Brian Marquis, Project Officer, National
Institute on Drug Abuse, 6001 Executive
Boulevard, Room 5216, Bethesda, MD
20892, or call non-toll-free number 301–
443–1124; fax 301–443–7397; or by email to bmarquis@/nida.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60-days of the date of
this publication.
Donna Jones,
Budget Officer & Acting Associate Director
for Management, National Institute on Drug
Abuse.
[FR Doc. 07–357 Filed 1–29–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
ycherry on PROD1PC64 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Megakaryocyte Potentiation Factor as a
New Serum Tumor Marker for
Mesothelioma
Description of Technology:
Mesothelin is a glycoprotein, whose
expression has been largely restricted to
mesothelial cells in normal tissues,
although epithelial cells of the trachea,
tonsil, fallopian tube, and kidney have
shown immunoreactivity. Mesothelin
has been shown to be expressed in
several cancers including mesothelioma,
lung cancer, pancreatic carcinomas,
gastric carcinomas and ovarian
carcinomas, and has the potential of
being used as a tumor marker and a
novel target for the development of new
treatments.
Mesothelin precursor protein is a 69
kDa protein that is proteolytically
cleaved into two products, the
megakaryocyte potentiation factor
(MPF) and mesothelin. MPF is a 33 kDa
soluble protein that is shed into the
blood stream of patients with
mesotheliomas and other tumors
including ovarian and pancreatic and
thus can be used as a serum marker for
the diagnosis of mesothelin expressing
cancers.
This invention describes the
generation of monoclonal antibodies to
MPF. The antibodies can be useful for
diagnosing mesotheliomas and other
cancers. Additionally, it can be used by
the oncological research community as
a research tool.
Applications: New monoclonal
antibodies against MPF; A new
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
monoclonal antibody against MPF that
can be used for diagnosis method for
mesotheliomas and other cancers
including ovarian and pancreatic by
detecting MPF in serum of patients.
Market: Cancer diagnostic market is
projected to grow to approximately $8B
in the next 5 years; Potential as a
research tool for oncology research
market.
Inventor: Ira H. Pastan et al. (NCI).
Publication: M Onda et al.
Megakaryocyte potentiation factor
cleaved from mesothelin precursor is a
useful tumor marker in the serum of
patients with mesothelioma. Clin
Cancer Res. 2006 Jul 15;12 (14 Pt
1):4225–4231.
Patent Status: HHS Reference No. E–
293–2006/0—Research Tool.
Licensing Status: Available for
licensing under a Biological Materials
license.
Licensing Contact: Jesse S. Kindra,
J.D.; 301/435–5559;
kindraj@mail.nih.gov.
Enriched Natural Killer Cells for
Adoptive Infusion Cancer Therapy
Description of Technology: Immunotherapy has taken a lead among the new
cancer therapeutic approaches. It is one
of the most promising new therapeutic
approaches that exploit the innate
immune mechanism of an individual to
fight against a certain disease.
Natural killer (NK) cells are a form of
cytotoxic lymphocytes which constitute
a major portion of the innate immune
system. NK cells have tumor cytotoxic
properties independent of tumor
specific antigens and have been shown
in murine models to control and prevent
tumor growth and dissemination.
Inactivation of NK cells potentially
allows cancer cells to evade host NKcell-mediated immunity. Ligation of
killer immunoglobulin like receptors
(KIRs) by MHC class I on both normal
and malignant tissues suppresses the
function of NK cells.
The present invention relates to
treating cancer and other
hyperproliferative disorders by
administering an enriched composition
of allogeneic or autologous (KIR/KIR
ligand incompatible) NK cell
population. This enriched composition
can potentially override the inactivation
E:\FR\FM\30JAN1.SGM
30JAN1
ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
of NK cells by self HLA molecules or
MHC class I expressing tumors. Claims
cover compositions of enriched NK cell
populations and method of treating
malignancies or prevent recurrence of
malignancies and treating any
hyperproliferative disorders with these
enriched compositions. Claims also
cover a method to sensitize
malignancies to NK cell TRAILmediated killing by pretreatment with
bortezomib.
Applications and Modality: New
adoptive infusion immunotherapeutic
method for treating solid tumors; New
cancer treatment method exploiting the
function of NK cells; Enriched
composition of allogeneic and
autologous NK cell population;
Enriched NK cell composition has
potential to override the natural NK cell
inactivation process by HLA or MHC
class I expressing tumors; Sensitizing
cancers to adoptively infused NK cells
by treatment with bortezomib as a
method to sensitize to NK cell TRAIL
cytotoxicity.
Market: In 2006, 600,000 estimated
deaths from cancer related diseases;
Immunotherapy market is expected to
double in the next 5 years; Adoptive
immunotherapy is one of the most
promising new cancer therapies.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Richard W. Childs et al.
(NHLBI).
Related Publications: 1. T Igarashi et
al. Enhanced cytotoxicity of allogeneic
NK cells with killer immunoglobulinlike receptor ligand incompatibility
against melanoma and renal cell
carcinoma cells. Blood. 2004 Jul
1;104(1):170–177.
2. A Lundqvist et al. Bortezomib and
depsipeptide sensitize tumors to tumor
necrosis factor-related apoptosisinducing ligand: a novel method to
potentiate natural killer cell tumor
cytotoxicity. Cancer Res. 2006 Jul
15;66(14):7317–7325.
3. A Lundqvist et al. Reduction of
GVHD and enhanced anti-tumor effects
after adoptive infusion of alloreactive
Ly49-mismatched NK-cells from MHCmatched donors. Blood. Prepublished
online 2006 Dec 19, doi 10.1182/blood2006–05–024315.
Patent Status: PCT Application No.
PCT/ U.S. 2005/039282 filed 31 Oct
2005, entitled ‘‘Compositions and
Methods for Treating Hyperproliferative
Disorders,’’ which published as WO
2006/050270 on 11 May 2006 (HHS
Reference No. E–183–2004/1–PCT–01).
Licensing Status: Available for
exclusive and non-exclusive licensing.
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
Licensing Contact: Thomas P. Clouse,
J.D.; 301/435–4076;
clousetp@mail.nih.gov.
Collaborative Research Opportunity:
The Hematology Branch of the National
Heart, Lung, and Blood Institute is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
use of in vitro expanded adoptively
infused NK cells to treat advanced and
incurable cancers. Please contact Dr.
Richard W. Childs at 301–496–5093 or
301–451–7128 (e-mail: childsr@nih.gov)
for more information.
Dated: January 19, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–1377 Filed 1–29–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Diagnostics and Therapeutics for
Hydrocephalus
Description of Technology: Congenital
hydrocephalus is a significant public
health problem, affecting approximately
one in 500 live births in the United
States. Congenital hydrocephalus has an
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
4275
adverse effect on the developing brain
and may persist as neurological defects
in children and adults. Some of these
defects may manifest as mental
retardation, cerebral palsy, epilepsy and
visual disabilities. Improved diagnostics
are needed for assessing the risks of
developing this debilitating disease.
The inventors have shown that
RFX4_v3, a splice variant of the
Regulatory Factor X4 (RFX4)
transcription factor, is associated with
the development of neurological
structures. The reduction or absence of
RFX4-v3 promotes the development of
congenital hydrocephalus. This
invention describes RFX4_v3
polypeptides and nucleic acids, as well
as methods for detection of RFX4_v3
polymorphisms associated with
congenital hydrocephalus. Also
described are treatment methods
including the RFX4-v3 polypeptide and
RFX4-v3 transgenic animals and
antibodies.
Applications: Prenatal diagnostic
assay for identifying children at risk for
congenital hydrocephalus; Genotyping
assay for congenital hydrocephalus.
Market: In the United States, the
health care costs for congenital
hydrocephalus are estimated at $100
million per year.
Development Status: In vitro data are
available.
Inventors: Perry J. Blackshear, Darryl
C. Zeldin, Joan P. Graves, and Deborah
J. Stumpo (NIEHS).
Publications:
1. Perry J. Blackshear et al. Graded
phenotypic response to partial and
complete deficiency of a brain-specific
transcript variant of the winged helix
transcription factor RFX4. Development.
2003 Oct;130(19):4539–4552.
2. Donghui Zhang et al. Identification
of potential target genes for RFX4_v3, a
transcription factor critical for brain
development. J Neurochem. 2006
Aug;98(3):860–875.
3. Donghui Zhang et al. Regulatory
factor X4 variant 3 (RFX4_v3): a
transcription factor involved in brain
development and disease. Submitted for
publication, Journal of Neuroscience
Research.
Patent Status: PCT Application No.
PCT/US03/12348 filed 18 Apr 2003,
which published as WO 03/088919 on
30 Oct 2003 (HHS Reference No. E–163–
2002/2–PCT–01); U.S. Patent
Application No. 10/511,362 filed 15 Oct
2004, which published as U.S. 2005/
0181369 on 18 Aug 2005 (HHS
Reference No. E–163–2002/2–US–02).
Licensing Status: Available for
exclusive or nonexclusive licensing.
Licensing Contact: Tara Kirby, Ph.D.;
301/435–4426; tarak@mail.nih.gov.
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Pages 4274-4275]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1377]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Megakaryocyte Potentiation Factor as a New Serum Tumor Marker for
Mesothelioma
Description of Technology: Mesothelin is a glycoprotein, whose
expression has been largely restricted to mesothelial cells in normal
tissues, although epithelial cells of the trachea, tonsil, fallopian
tube, and kidney have shown immunoreactivity. Mesothelin has been shown
to be expressed in several cancers including mesothelioma, lung cancer,
pancreatic carcinomas, gastric carcinomas and ovarian carcinomas, and
has the potential of being used as a tumor marker and a novel target
for the development of new treatments.
Mesothelin precursor protein is a 69 kDa protein that is
proteolytically cleaved into two products, the megakaryocyte
potentiation factor (MPF) and mesothelin. MPF is a 33 kDa soluble
protein that is shed into the blood stream of patients with
mesotheliomas and other tumors including ovarian and pancreatic and
thus can be used as a serum marker for the diagnosis of mesothelin
expressing cancers.
This invention describes the generation of monoclonal antibodies to
MPF. The antibodies can be useful for diagnosing mesotheliomas and
other cancers. Additionally, it can be used by the oncological research
community as a research tool.
Applications: New monoclonal antibodies against MPF; A new
monoclonal antibody against MPF that can be used for diagnosis method
for mesotheliomas and other cancers including ovarian and pancreatic by
detecting MPF in serum of patients.
Market: Cancer diagnostic market is projected to grow to
approximately $8B in the next 5 years; Potential as a research tool for
oncology research market.
Inventor: Ira H. Pastan et al. (NCI).
Publication: M Onda et al. Megakaryocyte potentiation factor
cleaved from mesothelin precursor is a useful tumor marker in the serum
of patients with mesothelioma. Clin Cancer Res. 2006 Jul 15;12 (14 Pt
1):4225-4231.
Patent Status: HHS Reference No. E-293-2006/0--Research Tool.
Licensing Status: Available for licensing under a Biological
Materials license.
Licensing Contact: Jesse S. Kindra, J.D.; 301/435-5559;
kindraj@mail.nih.gov.
Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy
Description of Technology: Immuno-therapy has taken a lead among
the new cancer therapeutic approaches. It is one of the most promising
new therapeutic approaches that exploit the innate immune mechanism of
an individual to fight against a certain disease.
Natural killer (NK) cells are a form of cytotoxic lymphocytes which
constitute a major portion of the innate immune system. NK cells have
tumor cytotoxic properties independent of tumor specific antigens and
have been shown in murine models to control and prevent tumor growth
and dissemination. Inactivation of NK cells potentially allows cancer
cells to evade host NK-cell-mediated immunity. Ligation of killer
immunoglobulin like receptors (KIRs) by MHC class I on both normal and
malignant tissues suppresses the function of NK cells.
The present invention relates to treating cancer and other
hyperproliferative disorders by administering an enriched composition
of allogeneic or autologous (KIR/KIR ligand incompatible) NK cell
population. This enriched composition can potentially override the
inactivation
[[Page 4275]]
of NK cells by self HLA molecules or MHC class I expressing tumors.
Claims cover compositions of enriched NK cell populations and method of
treating malignancies or prevent recurrence of malignancies and
treating any hyperproliferative disorders with these enriched
compositions. Claims also cover a method to sensitize malignancies to
NK cell TRAIL-mediated killing by pretreatment with bortezomib.
Applications and Modality: New adoptive infusion immunotherapeutic
method for treating solid tumors; New cancer treatment method
exploiting the function of NK cells; Enriched composition of allogeneic
and autologous NK cell population; Enriched NK cell composition has
potential to override the natural NK cell inactivation process by HLA
or MHC class I expressing tumors; Sensitizing cancers to adoptively
infused NK cells by treatment with bortezomib as a method to sensitize
to NK cell TRAIL cytotoxicity.
Market: In 2006, 600,000 estimated deaths from cancer related
diseases; Immunotherapy market is expected to double in the next 5
years; Adoptive immunotherapy is one of the most promising new cancer
therapies.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Richard W. Childs et al. (NHLBI).
Related Publications: 1. T Igarashi et al. Enhanced cytotoxicity of
allogeneic NK cells with killer immunoglobulin-like receptor ligand
incompatibility against melanoma and renal cell carcinoma cells. Blood.
2004 Jul 1;104(1):170-177.
2. A Lundqvist et al. Bortezomib and depsipeptide sensitize tumors
to tumor necrosis factor-related apoptosis-inducing ligand: a novel
method to potentiate natural killer cell tumor cytotoxicity. Cancer
Res. 2006 Jul 15;66(14):7317-7325.
3. A Lundqvist et al. Reduction of GVHD and enhanced anti-tumor
effects after adoptive infusion of alloreactive Ly49-mismatched NK-
cells from MHC-matched donors. Blood. Prepublished online 2006 Dec 19,
doi 10.1182/blood-2006-05-024315.
Patent Status: PCT Application No. PCT/ U.S. 2005/039282 filed 31
Oct 2005, entitled ``Compositions and Methods for Treating
Hyperproliferative Disorders,'' which published as WO 2006/050270 on 11
May 2006 (HHS Reference No. E-183-2004/1-PCT-01).
Licensing Status: Available for exclusive and non-exclusive
licensing.
Licensing Contact: Thomas P. Clouse, J.D.; 301/435-4076;
clousetp@mail.nih.gov.
Collaborative Research Opportunity: The Hematology Branch of the
National Heart, Lung, and Blood Institute is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the use of in
vitro expanded adoptively infused NK cells to treat advanced and
incurable cancers. Please contact Dr. Richard W. Childs at 301-496-5093
or 301-451-7128 (e-mail: childsr@nih.gov) for more information.
Dated: January 19, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-1377 Filed 1-29-07; 8:45 am]
BILLING CODE 4140-01-P
